{"schema_version":"secwatch.filing_event.v1","accession":"0001651308-23-000152","form_type":"8-K","ticker":"ONC","cik":"0001651308","company_name":"BeOne Medicines Ltd.","filed_at":"2023-10-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.941676+00:00","generated_at":"2026-06-09T18:38:42.897927+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"BeiGene's BRUKINSA receives positive NICE recommendation for CLL in UK","bullets":["NICE final draft guidance recommends BRUKINSA for untreated CLL with 17p deletion or TP53 mutation, or when FCR/BR unsuitable, and for relapsed or refractory CLL.","NICE found zanubrutinib cost-effective vs other BTK inhibitors, with lower incremental costs and more QALYs.","Follows NICE's July 2022 recommendation for Waldenstrom's macroglobulinemia and Scottish Medicines Consortium approval on Oct 9, 2023.","BRUKINSA approved in over 65 countries; global development program includes 5,000+ subjects in 29 countries."],"urls":{"canonical":"https://secwatch.observer/filing/0001651308-23-000152","json":"https://secwatch.observer/filing/0001651308-23-000152.json","markdown":"https://secwatch.observer/filing/0001651308-23-000152.md","text":"https://secwatch.observer/filing/0001651308-23-000152.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1651308/000165130823000152/0001651308-23-000152-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1651308/000165130823000152/bgne-20231020.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T18:38:42.897927+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}